Eli Lilly and Company (NYSE: LLY) today announced the successful completion of its acquisition of Verve Therapeutics, Inc.

Eli Lilly and Company has acquired Verve Therapeutics Inc., a Boston-based clinical-stage company developing genetic ...

Verve Therapeutics, Inc. (NASDAQ:VERV) is one of the Stocks With Huge Catalysts on the Horizon. On April 14, Verve ...

Eli Lilly's acquisition of Vere Therapeutics promises to revolutionize cardiovascular care with innovative one-time gene ...

Eli Lilly and Company (NYSE: LLY) and Verve Therapeutics, Inc. (NASDAQ: VERV) today announced that the tender offer to ...

We came across a bullish thesis on Verve Therapeutics, Inc. on Stock Region Research’s Substack by Stock Region. In this article, we will summarize the bulls’ thesis on VERV. Verve Therapeutics, ...

If Verve Therapeutics' dramatic stock price activity left your head spinning, you're not alone. Let's take a closer look at what happened so it isn't so easy to get caught off guard in the future.

Verve Therapeutics is a gene editing company focused on revolutionizing the treatment of cardiovascular diseases. The company’s research focuses on two genes, PCSK9 and ANGPTL3 - the lead ...

Shares of Verve Therapeutics VERV increased11.21% on Jul 20 after the company announced a collaboration with biotech giant Vertex Pharmaceuticals VRTX to develop a gene editing program for a liver ...

Verve Therapeutics, on the march toward the clinic with a next-gen heart drug, wants a piece of the ever-growing biotech IPO pie. Verve debuted just over two years ago with $58.5 million and a ...

Short interest in Verve Therapeutics, Inc. - Common Stock Corp (XNAS:VERV) decreased during the last reporting period, falling from 280.30M to 275.20M. This put 1.17% of the company's publicly ...

If Verve Therapeutics' dramatic stock price activity left your head spinning, you're not alone. Let's take a closer look at what happened so it isn't so easy to get caught off guard in the future.